• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Varian shares droop on Q1 miss

Varian shares droop on Q1 miss

January 26, 2017 By Fink Densford

Varian Medical SystemsShares in Varian Medical (NYSE:VAR) fell today after the medical device maker missed expectations on Wall Street with its 1st quarter earnings.

The Palo Alto, Calif.-based company posted profits of $21 million, or 22¢ per share, on sales of $763.3 million for the 3 months ended December 30. That amounts to a bottom-line slide of 76.4% while sales grew 0.8% compared with the same period last year.

After adjusting to exclude 1-time items, earnings per share were 75¢, significantly behind the $1.05 consensus on The Street, where analysts were looking for sales of $766.4 million.

“Varian generated strong global order growth and margin gains in our oncology business as well as sales momentum in the imaging components business while recording an impairment of CPTC’s indebtedness to Varian. We remain on track with our previously announced plans to separate and establish the imaging components business as a new public company, Varex Imaging, at the end of this month. We believe this center can get on a more solid financial footing by serving a broader patient population with additional healthcare providers locally and regionally. We remain confident and committed to supporting all of our customers and to building a profitable proton business based on leading technology that is treating patients and performing at a high level.  We are continuing to make good progress on 13 other installations and the sales funnel continues to look promising,” CEO Dow Wilson said in a press release.

Varian said it expects to see adjusted EPS of between 84¢ and 90¢ for the next quarter and between $2.94 and $3.06 for the full year. The company said it intends to repurchase 2 million shares of stock during its 2nd quarter.

VAR shares were trading at $86.84 apiece today in mid-day trading, down 6%.

Earlier this month, shares in Varex Imaging (NSDQ:VREXV), the $600 million components business spun out of Varian Medical, hit the market for their 1st day of public trading.

Stock in Salt Lake City-based Varex debuted Jan. 20 at $28 apiece, hitting a high of $28.50 before closing up 0.5% at $28.15 per share. Varian said earlier this month that it expects the spinout, accomplished via a tax-free distribution of shares such that each stockholder receives 0.4 shares of Varex for each Varian share, to be complete Jan. 28. The stock is slated to begin normal trading under the “VREX” symbol Jan. 30.

Filed Under: Business/Financial News Tagged With: Varian Medical Systems

More recent news

  • NICE recommends Boston Scientific Farapulse pulsed field ablation tech
  • SS Innovations completes first robotic telesurgery for weight loss
  • Johnson & Johnson MedTech adds new CMO for its Electrophysiology business
  • Abbott earns Medicare win for TriClip TEER system
  • Judge says Johnson & Johnson Ethicon owes $76.6M to ChemImage after failed partnership

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy